RT info:eu-repo/semantics/article
T1 Targeting insulin-degrading enzyme in insulin clearance
A1 Leissring, Malcolm A.
A1 González Casimiro, Carlos Manuel
A1 Merino Antolín, Beatriz
A1 Suire, Caitlin N.
A1 Perdomo Hernández, Germán
K1 Insulin
K1 Insulina
K1 Diabetes
K1 Insulin resistance
K1 Liver
K1 Liver - Diseases
K1 Hígado - Enfermedades
K1 Enzyme inhibitors
K1 Enzimas
K1 Hepatología
K1 Pharmacology
K1 Insulin-degrading enzyme
K1 32 Ciencias Médicas
K1 2415 Biología Molecular
AB Hepatic insulin clearance, a physiological process that in response to nutritional cues clears ~50–80% of circulating insulin, is emerging as an important factor in our understanding of the pathogenesis of type 2 diabetes mellitus (T2DM). Insulin-degrading enzyme (IDE) is a highly conserved Zn2+-metalloprotease that degrades insulin and several other intermediate-size peptides. Both, insulin clearance and IDE activity are reduced in diabetic patients, albeit the cause-effect relationship in humans remains unproven. Because historically IDE has been proposed as the main enzyme involved in insulin degradation, efforts in the development of IDE inhibitors as therapeutics in diabetic patients has attracted attention during the last decades. In this review, we retrace the path from Mirsky’s seminal discovery of IDE to the present, highlighting the pros and cons of the development of IDE inhibitors as a pharmacological approach to treating diabetic patients.
PB MDPI
SN 1422-0067
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/59963
UL https://uvadoc.uva.es/handle/10324/59963
LA eng
NO International Journal of Molecular Sciences, 2021, Vol. 22, Nº. 5, 2235
NO Producción Científica
DS UVaDOC
RD 24-nov-2024